Horizon therapeutics public limited company (HZNP)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Net sales

1,300,029

1,207,570

1,056,231

981,120

757,044

296,955

74,016

18,844

6,927

2,376

Cost of goods sold

362,175

391,301

493,368

392,001

219,502

78,753

14,625

11,875

7,267

4,263

Sale of goods

-

-

-

-

-

-

-

-

-

2,376

Gross sales

-

-

-

-

-

-

-

-

6,939

2,376

Sales discounts and allowances

-

-

-

-

-

-

-

-

12

-

Gross profit

937,854

816,269

562,863

589,119

537,542

218,202

59,391

6,969

-340

-1,887

OPERATING EXPENSES:
Research and development

103,200

82,800

225,000

60,707

41,865

17,460

10,084

16,837

15,358

17,697

Selling, general and administrative

697,111

692,485

655,093

603,048

440,305

-

-

-

-

-

Loss (gain) on sale of assets

-10,963

42,985

-

-

-

-

-

-

-

-

Impairment of long-lived assets

-

46,096

22,270

71,260

-

-

-

-

-

-

Sales and marketing

-

-

-

-

-

120,276

68,595

49,561

20,314

5,558

General and administrative

-

-

-

-

-

88,957

23,566

19,444

15,008

18,612

Intangible impairment charge

-

-

-

-

-

-

-

-

69,621

-

Total operating expenses

811,243

778,358

902,325

735,015

482,170

226,693

102,245

85,842

120,301

41,867

Operating loss

126,611

37,911

-339,462

-145,896

55,372

-8,491

-42,854

-78,873

-120,641

-43,754

OTHER EXPENSE, NET:
Interest expense, net

-87,089

-121,692

-126,523

-86,610

-69,900

-23,826

-12,774

11,552

6,284

3,024

Loss on debt extinguishment

-58,835

-

-978

-

-

-

-

-

-

-

Gain on divestiture

-

-

7,965

-

-

-

-

-

-

-

Foreign exchange gain (loss)

33

-192

-260

-1,005

-1,237

-3,905

1,206

489

-1,023

-273

Loss on induced conversion of debt and debt extinguishment

-

-

-

-

-77,624

-29,390

-26,404

-2,973

-

-

Loss on sale of long-term investments

-

-

-

-

-29,032

0

0

-

-

-

Bargain purchase gain

-

-

-

-

-

22,171

-

-

-

19,326

Loss on derivative fair value

-

-

-

-

-

214,995

69,300

-

-

-

Other income, net

-944

841

447

6,697

-10,291

-11,251

-

-56

-

-

Total other expense, net

-146,835

-121,043

-119,349

-80,918

-188,084

-261,196

-107,272

-14,092

-7,307

16,029

Loss before benefit for income taxes

-20,224

-83,132

-458,811

-226,814

-132,712

-269,687

-150,126

-92,965

-127,948

-27,725

Benefit for income taxes

-593,244

-44,752

-108,686

-61,251

-172,244

-6,084

-1,121

-5,171

-14,683

-660

Net loss

573,020

-38,380

-350,125

-165,563

39,532

-263,603

-149,005

-87,794

-113,265

-27,065

Net loss per ordinary share—basic and diluted

-

-

-

-1.03

-

-

-

-2.26

-12.56

-21.16

Weighted average ordinary shares outstanding—basic and diluted

-

-

-

160,699

-

-

-

38,871

9,014

1,279

Net income (loss) per ordinary share—basic

3.13

-0.23

-2.15

-

0.27

-3.15

-2.34

-

-

-

Weighted average ordinary shares outstanding—basic

182,930

166,155

163,122

-

148,788

83,751

63,657

-

-

-

Net income (loss) per ordinary share—diluted

2.90

-0.23

-2.15

-

0.25

-3.15

-2.34

-

-

-

Weighted average ordinary shares outstanding—diluted

205,224

166,155

163,122

-

155,923

83,751

63,657

-

-

-

OTHER COMPREHENSIVE LOSS, NET OF TAX
Foreign currency translation adjustments

-382

-826

2,067

-302

1,712

-1,960

969

416

-1,559

-2,230

Pension remeasurements

-

-286

-36

133

-

-

-

-

-

-

Other comprehensive loss

-382

-540

2,103

-435

1,712

-1,960

969

416

-1,559

-2,230

Comprehensive loss

572,638

-38,920

-348,022

-165,998

41,244

-265,563

-148,036

-87,378

-114,824

-29,295